Venous thromboembolism in malignant gliomas

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 2, 2010, Pages 221-227

  Jenkins, E O ^a   Schiff, D ^b   Mackman, N ^a   Key, N S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bevacizumab; Malignant glioma; Thromboembolism; Tissue factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CORTICOSTEROID; DALTEPARIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRIN; IXOLARIS; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLASMINOGEN ACTIVATOR; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CANCER GRADING; CELL MIGRATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG MECHANISM; EDEMA; FILTER; GENE EXPRESSION; GLIOBLASTOMA; HOSPITAL PATIENT; HUMAN; INFERIOR CAVA VEIN; LUNG EMBOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOGENESIS; TUMOR CELL; TUMOR VOLUME; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTICOAGULANTS; BLOOD COAGULATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; INTRACRANIAL HEMORRHAGES; NEUROSURGICAL PROCEDURES; RISK ASSESSMENT; RISK FACTORS; STOCKINGS, COMPRESSION; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 74749106182     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03690.x     Document Type: Review

References (97)

1. Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Current Treat Options Oncol 2004, 5:511-7.
2. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol 2006, 80:313-32.
3. Tabori U, Beni-Adani L, Dvir R, Burstein Y, Feldman Z, Pessach I, Rechavi G, Constantini S, Toren A. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004, 43:633-6.
4. Marras CL, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 2000, 89:640-6.
5. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV. Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer 1997, 33:1592-6.
6. Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I, Marosi C. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 2007, 9:89-95.
7. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006, 24:1310-8.
8. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007, 106:601-8.
9. Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006, 24:1112-8.
10. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983, 13:334-6.
11. Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004, 100:1717-23.
12. Rodas RA, Fenstermaker RA, McKeever PE, Blaivas M, Dickinson LD, Papadopoulos SM, Hoff JT, Hopkins LN, Duffy-Fronckowiak M, Greenberg HS. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg 1998, 89:200-5.
13. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thromb Haemost 1993, 70:393-6.
14. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med 2001, 7:326-31.
15. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-5.
16. Elice F, Jacoub J, Rickles FR, Falanga A, Rodeghiero F. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 2008, 83:862-70.
17. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005, 69(Suppl. 3):25-33.
18. Khorana AA, Rao MV. Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res 2007, 120(Suppl. 2):41-50.
19. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-9.
20. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Alfred Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-40.
21. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25:5490-505.
22. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005, 23:2574-6.
23. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with angiogenesis inhibitor Bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300:2277-85.
24. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JH. Prognosis of cancers associated with venous thromboembolism. N Eng J Med 2000, 343:1846-50.
25. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006, 166:458-64.
26. Dietcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 2003, 16:21-31.
27. Ghanim AJ, Daskalakis C, Eschelman DJ, Kraft WK. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis 2007, 24:247-54.
28. Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998, 43:1074-81.
29. Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcomes. J Clin Oncol 1996, 14:652-7.
30. Lin J, Proctor MC, Varma M, Greenfield LJ, Upchurch GR, Henke PK. Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vasc Surg 2003, 23:976-83.
31. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994, 73:493-8.
32. Spyropoulos AC, Brotman DJ, Amin AN, Dietelzweig SB, Jaffer AK, McKean SC. Prevention of venous thromboembolism in the cancer surgery patient. Cleve Clin J Med 2008, 3(Suppl. 3):17-26.
33. Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vasc Endovascular Surg 2006, 40:287-94.
34. Cavaliere R, Schiff D. Fatal pulmonary embolism despite an inferior vena cava filter in gliobastoma multiforme. Neurocrit Care 2005, 3:249-50.
35. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993, 43:1111-4.
36. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008, 10:355-60.
37. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Eng J Med 1998, 339:80-5.
38. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002, 122:1933-7.
39. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl. 6):381-453.
40. Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost 2005, 94:867-71.
41. Cohen AT, Alikhan R, Arcelus JI, Begmann JF, Haas S, Merli GJ, Spyropoulos AC, Tapson VF, Turpie AG. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005, 94:750-9.
42. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994, 343:886-9.
43. Agnelli G, Verso M. Thromboprophylaxis during chemotherapy after advanced cancer. Thromb Res 2007, 120(Suppl. 2):128-32.
44. Perry JR, Rogers L, Laperriere N, Julian J, Geerts W, Agnelli G, Malkin M, Sawaya R, Baker R, Levine M. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol 2007, 25(Suppl.). ASCO Annual Meeting Proceedings
45. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111:4902-7.
46. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004, 2:2156-61.
47. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study. J Clin Oncol 2009, 27:4124-9.
48. Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, Shiku H. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002, 69:247-54.
49. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness of human hepatocellular carcinoma. Clin Cancer Res 2003, 9:5339-45.
50. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB. Tissue factor expression, angiogenesis and thrombosis in pancreatic cancer. Clin Cancer Res 2007, 13:2870-5.
51. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. Cancer 2007, 110:1149-60.
52. Robins HI, O'Neill A, Gilbert M, Olsen M, Sapiente R, Berkey B, Mehta M. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008, 62:227-33.
53. Frank RD, Schabbauer G, Holscher T, Sato Y, Tencati M, Pawlinski R, Mackman N. The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. J Thromb Haemost 2005, 3:531-40.
54. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002, 110:127-36.
55. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic agents. Nat Rev Cancer 2005, 5:526-42.
56. Borsig L, Wong R, Feramisco R, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001, 98:3352-7.
57. Tehrani M, Friedman TM, Olson JJ, Brat DJ. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol 2008, 18:164-71.
58. Rong Y, Post DE, Pieper RO, Durden DL, van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005, 65:1406-13.
59. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, Mackman N. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001, 98:1429-39.
60. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, Pinsky DJ, Stern DM. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000, 6:1355-61.
61. Pawlinski R, Pedersen B, Kehrle B, Aird WC, Frank RD, Guha M, Mackman N. Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. Blood 2003, 101:3940-7.
62. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, van Meir EG, Mackman N, Brat DJ. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/Activator Protein-1 transcriptional activity. Cancer Res 2009, 69:2540-3549.
63. Milsom CC, Yu JL, Mackman N, Micallef J, Anderson GM, Guha A, Rak JW. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initation and angiogenesis. Cancer Res 2008, 68:100068-76.
64. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumor cells. Nat Cell Biol 2008, 10:619-24.
65. Carneiro-Lobo TC, Konig S, Machado DE, Nasciutti LE, Forni MF, Francischetti IMB, Sogayar MC, Monteiro RQ. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J Thromb Haemost 2009, 7:1855-64.
66. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007, 110:1723-9.
67. Furie B, Furie BC. Mechanisms of thrombus formation. N Eng J Med 2008, 359:938-49.
68. Thoron L, Arbit E. Hemostatic changes in patients with brain tumors. J Neurooncol 1994, 22:87-100.
69. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005, 6:401-10.
70. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996, 77:1877-83.
71. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005, 105:1734-41.
72. McEachron T, Mackman N. Tumors, ticks and tissue factor. J Thromb Haemost 2009, 7:1852-4.
73. Ruf W, Fischer EG, Huang HY, Miyagi Y, Ott I, Riewald M, Mueller BM. Diverse functions of protease receptor tissue factor in inflammation and metastasis. Immunol Res 2000, 21:289-92.
74. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-depedent and -independent mechanisms. Blood 2007, 110:133-41.
75. Gerber DE, Segal JB, Salhotra A, Olivi A, Grossman SA, Streiff MB. Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis. Cancer 2007, 109:300-5.
76. Rao JS, Rayford A, Morantz RA, Festoff BW, Sawaya R. Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. J Neurooncol 1993, 17:215-21.
77. Iberti TJ, Miller M, Abalos A, Fischer EP, Post KD, Benjamin E, Oropello JM, Wiltshire-Clement M, Rand JH. Abnormal coagulation profile in brain tumor patients during surgery. Neurosurgery 1994, 34:389-94.
78. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S, Parati E, Croci D, Boiardi A, Salmaggi A. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004, 10:1312-7.
79. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol 1989, 134:1087-97.
80. Eddleston M, De la Torre JC, Oldstone MB, Loskutoff DJ, Edgington TS, Mackman N. Astrocytes are the primary source of tissue factor in the murine central nervous system. J Clin Invest 1993, 92:349-58.
81. Tesselaar MT, Romijn FP, van der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2006, 5:520-7.
82. Tilley RE, Holscher T, Belani R, Nieva J, Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res 2008, 122:604-9.
83. Tesselaar MT, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007, 13:362-7.
84. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA, Weltermann A. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007, 97:119-23.
85. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004, 2:2065-7.
86. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008, 6:1517-24.
87. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007, 5:2445-52.
88. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis and warfarin. J Clin Oncol 2003, 21:3543.
89. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009, 7:171-81.
90. Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, De Martin R, Binder BR, Hofer E. Specificity, diversity, and convergence in VEGF and TNF-a signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001, 15:230-42.
91. Armesilla AL, Lorenzo E, Gomez del Arco P, Martinez-Martinez S, Alfranca A, Redondo JM. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol 1999, 19:2032-43.
92. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005, 25:1545-50.
93. Chen J, Kasper M, Heck T, Nakagawa K, Humpert PM, Bai L, Wu G, Zhang Y, Luther T, Andrassy M, Schiekofer S, Hamann A, Morcos M, Chen B, Stern DM, Nawroth PP, Bierhaus A. Tissue factor as a link between wounding and tissue repair. Diabetes 2005, 54:2143-54.
94. Ustuner Z, Saip P, Yasasever V, Vural B, Yazar A, Bal C, Ozturk B, Ozbek U, Topuz E. Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol 2008, 25:394-9.
95. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007, 14:1835-45.
96. Ascierto PA, Leonardi E, Ottaiano A, Napolitano M, Scala S, Castello G. Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res 2004, 24:4255-8.
97. Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 2008, 10:700-8.